Eli Lilly forays into radiopharmaceuticals with $1.4B POINT buy

Oct 3, 2023 · Eli Lilly will acquire POINT Biopharma as the drugmaker looks to definitively expand its oncology capabilities into next-gen radioligand therapies. Per the agreement, Lilly will …

CouponFollow Extension

$1
OFF

Eli Lilly Forays Into Radiopharmaceuticals With $1.4B POINT Buy

4 weeks from now

Oct 3, 2023 · Eli Lilly will acquire POINT Biopharma as the drugmaker looks to definitively expand its oncology capabilities into next-gen radioligand therapies. Per the agreement, Lilly will …

pharmamanufacturing.com

$1
OFF

Eli Lilly Jumps Into Radiopharmaceuticals Via $1.4B Point …

4 weeks from now

Oct 3, 2023 · Eli Lilly’s scope in cancer is expanding to radiopharmaceuticals with the $1.4 billion acquisition of Point Biopharma Global, a company in late-stage clinical development with two …

medcitynews.com

$140
OFF

Eli Lilly Continues Radiopharma Push With $140m Radionetics …

4 weeks from now

Jul 2, 2024 · The deal marks the latest push by Eli Lilly into the radiopharmaceuticals space. The company spent $1.4bn to buy POINT Biopharma in October 2023, gaining two late-stage …

pharmaceutical-technology.com

$1
OFF

How Novartis Is Disrupting Lilly's $1.4B Radiotherapy Plan - Fierce …

4 weeks from now

Dec 5, 2023 · On Oct. 3, Eli Lilly unveiled a $1.4 billion agreement to acquire cross-town radiopharmaceutical company Point Biopharma Global to beef up its oncology capabilities. …

fiercebiotech.com

$1
OFF

Eli Lilly Inks Another Radiopharma Deal, Gaining Option To Buy Startup

4 weeks from now

Jul 1, 2024 · Eli Lilly is expanding further into radiopharmaceuticals, inking a deal with Radionetics Oncology that gives it an option to later acquire the San Diego biotechnology company for $1 …

biopharmadive.com

$1
OFF

Eli Lilly Inks Deal Worth Over $1.1B To Develop New …

4 weeks from now

May 21, 2024 · Drugmaker Eli Lilly has inked a deal worth over $1 billion to develop new radiopharmaceuticals in concert with biotechnology firm Aktis Oncology. Under terms of the …

radiologybusiness.com

$150
OFF

The 1,552 NJ Superintendents, Principals Earning $150K Or More

4 weeks from now

The 1,552 NJ Superintendents, Principals Earning $150K Or More - Point Pleasant, NJ - These 1,552 NJ school superintendents and principals earned $150K or more, even if their districts …

patch.com

FAQs about Eli Lilly forays into radiopharmaceuticals with $1.4B POINT buy Coupon?

Will Eli Lilly buy point Biopharma?

Eli Lilly is making a bet on radiopharmaceutical drugs for cancer, announcing Tuesday a deal to buy Point Biopharma and its pipeline of experimental therapies for approximately $1.4 billion. Per acquisition terms, Lilly will pay $12.50 per Point share, a premium of about 87% to what the biotechnology company’s stock closed at Monday. ...

Will Eli Lilly buy radionetics oncology?

Scott Olson via Getty Images Eli Lilly is expanding further into radiopharmaceuticals, inking a deal with Radionetics Oncology that gives it an option to later acquire the San Diego biotechnology company for $1 billion. Lilly will pay Radionetics $140 million upfront for the option rights under the deal, which the companies announced Monday. ...

Will Eli Lilly buy a treatment for metastatic prostate cancer?

One of the experimental drugs Eli Lilly will acquire is a treatment for metastatic prostate cancer. Dr_Microbe via Getty Images Eli Lilly is making a bet on radiopharmaceutical drugs for cancer, announcing Tuesday a deal to buy Point Biopharma and its pipeline of experimental therapies for approximately $1.4 billion. ...

Could Lilly & point accelerate the development of radiopharmaceuticals?

Joe McCann, Ph.D., CEO of POINT added: "The combination of POINT's team, infrastructure and capabilities with Lilly's global resources and experience could significantly accelerate the discovery, development and global access to radiopharmaceuticals. ...

Will Lilly buy radionetics?

Radionetics will continue to build its radiopharmaceutical drug pipeline through an “exercise period,” after which Lilly can choose whether to acquire the company. Radionetics is developing small molecule radiopharmaceuticals that can target G protein-coupled receptors, a ubiquitous family of proteins that present many attractive disease targets. ...

Why is Lilly partnering with a pharma company to develop radiopharma?

Recent improvements in manufacturing and supplying the complex treatments have boosted investment in the field, drawing interest from large pharma companies like Lilly as well as new drug startups. The Point deal appears to be part of a broader plan by Lilly to build a presence in radiopharma drug development. ...